Summit Therapeutics报告了 Ivonescimab在肺癌治疗中的混合试验结果Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment

动脉网
30 May

by Mark Chiang马克·蒋Share To分享到Summit Therapeutics announced mixed results from a recent trial of its antibody treatment for lung cancer, Ivonescimab. The drug, which had previously outperformed Merck’s...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10